D
The startup utilizes artificial intelligence to provide early diagnosis of sepsis by identifying the causative infective agent and determining phenotypic antimicrobial susceptibility without prior cultivation. This approach reduces unnecessary antimicrobial use and enables timely treatment for patients in the critical early stages of the disease.
Barcelona, Spain
Updated 2 months ago
Funding
$40.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup utilizes artificial intelligence to provide early diagnosis of sepsis by identifying the causative infective agent and determining phenotypic antimicrobial susceptibility without prior cultivation. This approach reduces unnecessary antimicrobial use and enables timely treatment for patients in the critical early stages of the disease.